Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: Implications for future treatment options

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages 233-240

  Singh, Ashika ^a   Sunpath, Henry ^b   Green, Taryn N ^a   Padayachi, Nagavelli ^a   Hiramen, Keshni ^a   Lie, Yolanda ^c   Anton, Elizabeth D ^c   Murphy, Richard ^d   Reeves, Jacqueline D ^c   Kuritzkes, Daniel R ^e,f   Ndung'U, Thumbi ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b MCCORD HOSPITAL   (South Africa)

^c MONOGRAM BIOSCIENCES   (United States)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antiretroviral drug resistance; coreceptor use; HAART failing patients; HAART na ve patients; viral tropism

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; THYMIDINE; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SOUTH AFRICA; VIRAL TROPISM;

ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTANT PROTEINS; MUTATION, MISSENSE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECEPTORS, HIV; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; VIRAL TROPISM;

EID: 80054948254     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318228667f     Document Type: Article

References (43)

1. UNAIDS. AIDS epidemic update. 2007. Available at: www.unaids.org. Accessed February 18, 2008.
2. Taylor BS, Sobieszczyk ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008;358:1590-1602.
3. South Africa Government online: the Government and Information System. Available at: http://www.info.gov.za/otherdocs/2003/aidsplan/report.pdf. Accessed February 25, 2008.
4. UNAIDS Global Report. Factsheet-Sub-Saharan Africa. 2010. http://www.unaids.org/en/media/unaids/contentassets/documents/factsheet/2010/ 20101123-FS-SSA-em-en.pdf. Accessed May 11, 2011.
5. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622. (Pubitemid 29249430)
6. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005;79:9625-9634. (Pubitemid 41022306)
7. WHO recommendations for clinical mentoring to support scale-up of HIV care, antiretroviral therapy and prevention in resource-constrained settings. WHO Guidelines. 2006. Available at: http://www.who.int/hiv/pub/guidelines/ clinicalmentoring.pdf.
8. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis. 2009;200:687-697.
9. Hosseinipour MC, van Oosterhout JGG,Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing firstline antiretroviral therapy. AIDS. 2009;23:1127-1134.
10. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-1597. (Pubitemid 351706742)
11. Wallis C, Mellors JW, Venter F, et al. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53:480-484.
12. Hunt PW, Harrigan PR, Huang W, et al. Prevelence of CXCR4 tropism among antiretroviral-treated HIV-1-infected paitients with detectable viremia. J Inf Dis. 2006;194:926-930. (Pubitemid 44454078)
13. Johnston ER, Zijenah LS, Mutetwa S, et al. High frequency of syncytiuminducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol. 2003;77:7682-7688. (Pubitemid 36734540)
14. Connor RL, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628. (Pubitemid 27098147)
15. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression. Nat Med. 1997;3:1259-1265. (Pubitemid 27508828)
16. Bjorndal A, Sonnerborg A, Tscherning C, et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. Aids Res Hum Retroviruses. 1999;15:647-653. (Pubitemid 29205668)
17. Cecilia D, Kulkarni SS, Tripathy SP, et al. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology. 2000;271:253-258. (Pubitemid 30461303)
18. Cilliers T, Nhlapo J, Coetzer M, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003;77:4449-4456. (Pubitemid 36350986)
19. Ndung'u T, Sepako E, McLane MF, et al. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology. 2006;347:247-260.
20. Tscherning CA, Alaeus RF, Fredriksson A, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology. 1998;241:181-188.
21. Reeves JD, Coakley E, Petropoulos CJ, et al. An enhanced-sensitivity TrofileTM HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry. 2009;3:94-102.
22. Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antiviral Ther. 2008;13:128.
23. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis. 2005;18:9-15. (Pubitemid 41716234)
24. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir J Virol. 2006;80:4909-4920.
25. Singh A, Page T, Moore PL, et al. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology. 2009; 393:56-67.
26. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24: 1596-1599. (Pubitemid 47236692)
27. Coetzer M, Cilliers T, Ping LH, et al. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006;356:95-105. (Pubitemid 44750034)
28. Fouchier RA, Brouwer M, Broersen SM, et al. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol. 1995;33:906-911.
29. Fouchier RA, Groenink M, Kootstra NN, et al. Phenotype-associated sequence variationin the third variable domain of the human immunodeficiency virus type 1 gp 120 molecule. J Virol. 1992;66:3183-3187.
30. Kuiken CL, de Jong JJ, Baan E, et al. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol. 1992;66:5704.
31. Whitcomb J, Parkin N, Cheppey C, et al. Broad NRTI cross-resistance in HIV-1 clinical isolates. J Infect Dis. 2003;188:992-1000.
32. Stanford HIV Drug Resistance Database. Available at: http://hivb. stanford.edu/. Accessed May 11, 2009.
33. Novitsky V, Wester W, Degruttola V, et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in Southern Africa. AIDS Res Hum Retroviruses. 2007;23:868-878. (Pubitemid 47267493)
34. Briggs DR, Tuttle DL, Sleasman JW, et al. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS. 2000;14:2937-2939. (Pubitemid 32042758)
35. Cann AJ, Churcher MJ, Boyd M, et al. The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol. 1992;66:305-309.
36. Rizzuto C, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding Science. 1998;280:1949-1953. (Pubitemid 28299405)
37. Wu X, Parast AB, Richardson BA, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol. 2006;80:835-844. (Pubitemid 43062895)
38. Brenner B, Oliveira M, Moisi D, et al. AV106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross resistance to nonnucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-F5. (Pubitemid 36106291)
39. Kantor R, Katzenstein DA, Effron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112.
40. Loemba H, Brenner B, Parniak MA, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother. 2002;46:2087-2094. (Pubitemid 34665901)
41. Briz V, Poveda E, del Mar Gonzalez M, et al. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother. 2008;65:405-410.
42. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, et al. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS. 2008;22: 1425-1431.
43. Low AJ, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS. 2007;21:F17-F24. (Pubitemid 47329758)